Quick Answer
Cadrenal Therapeutics, Inc. reported Net Income Loss of -$13.24 million for the year ending 2025.
- Cadrenal Therapeutics, Inc. showed a decrease of -24.3% in Net Income Loss from 2024 to 2025.
- This data is from Cadrenal Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: -$176.6 thousand | Q2 2022: -$502.1 thousand | Q3 2022: -$1.03 million | Q1 2023: -$5.17 million | Q2 2023: -$1.00 million | Q3 2023: -$1.04 million | Q1 2024: -$1.66 million | Q2 2024: -$2.39 million | Q3 2024: -$2.41 million | Q1 2025: -$3.85 million | Q2 2025: -$3.67 million | Q3 2025: -$2.69 million.
- Over the full 4 years of available data (2022 to 2025), Cadrenal Therapeutics, Inc.'s Net Income Loss has declined by 97.2%.
- Historical annual values: Fiscal year 2025: -$13.24 million | Fiscal year 2024: -$10.65 million | Fiscal year 2023: -$8.36 million | Fiscal year 2022: -$6.71 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: